[go: up one dir, main page]

ES2120713T3 - Compuestos de isoxazolinas utiles como antagonistas de receptores del fibrinogeno. - Google Patents

Compuestos de isoxazolinas utiles como antagonistas de receptores del fibrinogeno.

Info

Publication number
ES2120713T3
ES2120713T3 ES95901913T ES95901913T ES2120713T3 ES 2120713 T3 ES2120713 T3 ES 2120713T3 ES 95901913 T ES95901913 T ES 95901913T ES 95901913 T ES95901913 T ES 95901913T ES 2120713 T3 ES2120713 T3 ES 2120713T3
Authority
ES
Spain
Prior art keywords
fibrinogen receptor
receptor antagonists
compounds useful
compounds
isoxazoline compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95901913T
Other languages
English (en)
Inventor
John Wityak
Sielecki-Dzurdz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Pharma Co
Original Assignee
DuPont Merck Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/304,614 external-priority patent/US5446056A/en
Application filed by DuPont Merck Pharmaceutical Co filed Critical DuPont Merck Pharmaceutical Co
Application granted granted Critical
Publication of ES2120713T3 publication Critical patent/ES2120713T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/04—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

ESTA INVENCION SE REFIERE A LAS NUEVAS ISOXAZOLINAS, UTILES COMO ANTAGONISTAS DEL COMPLEJO RECEPTOR DEL FIBRINOGENO TROMBOCITARIO GLICOPROTEICO IIB/IIIA, A LAS COMPOSICIONES FARMACEUTICAS QUE CONTIENEN ESTOS COMPUESTOS, PROCESOS PARA PREPARARLOS Y A LOS METODOS PARA UTILIZARLOS, POR SEPARADO O EN COMBINACION CON OTROS AGENTES TERAPEUTICOS, PARA LA INHIBICION DEL CONJUNTO DE TROMBOCITOS, COMO TROMBOLITICOS Y/O PARA EL TRATAMIENTO DE TRASTORNOS TROMBOEMBOLICOS.
ES95901913T 1993-11-24 1994-11-14 Compuestos de isoxazolinas utiles como antagonistas de receptores del fibrinogeno. Expired - Lifetime ES2120713T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15785193A 1993-11-24 1993-11-24
US08/304,614 US5446056A (en) 1993-11-24 1994-09-12 Isoxazoline compounds useful as fibrinogen receptor antagonists

Publications (1)

Publication Number Publication Date
ES2120713T3 true ES2120713T3 (es) 1998-11-01

Family

ID=26854532

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95901913T Expired - Lifetime ES2120713T3 (es) 1993-11-24 1994-11-14 Compuestos de isoxazolinas utiles como antagonistas de receptores del fibrinogeno.

Country Status (10)

Country Link
EP (1) EP0730589B1 (es)
JP (1) JPH09505589A (es)
AT (1) ATE168106T1 (es)
AU (1) AU677481B2 (es)
CA (1) CA2174415A1 (es)
DE (1) DE69411584T2 (es)
DK (1) DK0730589T3 (es)
ES (1) ES2120713T3 (es)
NZ (1) NZ276631A (es)
WO (1) WO1995014682A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
IL118007A0 (en) * 1995-05-24 1996-08-04 Du Pont Merck Pharma Isoxazoline compounds pharmaceutical compositions containing them and their use
ZA963391B (en) * 1995-05-24 1997-10-29 Du Pont Merck Pharma Isoxazoline fibrinogen receptor antagonists.
IL118325A0 (en) * 1995-05-25 1996-10-31 Pont Merck And Pharmaceutical Integrin receptor antagonists and pharmaceutical compositions containing them
US5939418A (en) * 1995-12-21 1999-08-17 The Dupont Merck Pharmaceutical Company Isoxazoline, isothiazoline and pyrazoline factor Xa inhibitors
JP2001502655A (ja) * 1995-12-21 2001-02-27 デュポン ファーマシューティカルズ カンパニー Ｘａ因子阻害薬であるイソオキサゾリン、イソチアゾリンおよびピラゾリン
ZA972195B (en) * 1996-03-15 1998-09-14 Du Pont Merck Pharma Spirocycle integrin inhibitors
CA2249733A1 (en) * 1996-03-15 1997-09-18 Du Pont Pharmaceuticals Company Spirocycle integrin inhibitors
JP2000516230A (ja) * 1996-08-15 2000-12-05 デュポン ファーマシューティカルズ カンパニー Ｉｉｂ／ｉｉｉａ拮抗薬としての環状カルバメート類およびイソオキサゾリジン類
AU724191B2 (en) * 1996-08-29 2000-09-14 Merck & Co., Inc. Integrin antagonists
US6214834B1 (en) 1997-03-28 2001-04-10 Dupont Pharmaceuticals Company Integrin inhibitor prodrugs
US7109326B2 (en) 1997-04-15 2006-09-19 Genentech, Inc. Halo-alkoxycarbonyl prodrugs
US5998424A (en) 1997-06-19 1999-12-07 Dupont Pharmaceuticals Company Inhibitors of factor Xa with a neutral P1 specificity group
ES2239806T3 (es) 1997-06-19 2005-10-01 Bristol-Myers Squibb Pharma Company Inhibidores del factor xa con un grupo de especificidad neutro p1.
ZA988735B (en) * 1997-10-06 2000-03-23 Du Pont Pharm Co An efficient method for the conversion of nitriles to amidines.
ATE278673T1 (de) * 1998-03-27 2004-10-15 Bristol Myers Squibb Pharma Co Disubstituierte pyrazoline und triazoline als faktor xa inhibitoren
CA2333647A1 (en) * 1998-06-29 2000-01-06 Dupont Pharmaceuticals Company Cyclic carbamates and isoxazolidines as iib/iiia antagonists
EP1131306A2 (en) 1998-11-18 2001-09-12 Du Pont Pharmaceuticals Company Isoxazoline fibrinogen receptor antagonists
US6319937B1 (en) * 1998-11-18 2001-11-20 Dupont Pharmaceuticals Company Isoxazoline fibrinogen receptor antagonists

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL99537A (en) * 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
DE4124942A1 (de) * 1991-07-27 1993-01-28 Thomae Gmbh Dr K 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US5239113A (en) * 1991-10-15 1993-08-24 Monsanto Company Substituted β-amino acid derivatives useful as platelet aggregation inhibitors and intermediates thereof

Also Published As

Publication number Publication date
CA2174415A1 (en) 1995-06-01
DE69411584D1 (de) 1998-08-13
AU1097895A (en) 1995-06-13
JPH09505589A (ja) 1997-06-03
NZ276631A (en) 1997-06-24
DE69411584T2 (de) 1998-12-17
DK0730589T3 (da) 1999-02-01
ATE168106T1 (de) 1998-07-15
AU677481B2 (en) 1997-04-24
EP0730589B1 (en) 1998-07-08
WO1995014682A1 (en) 1995-06-01
EP0730589A1 (en) 1996-09-11

Similar Documents

Publication Publication Date Title
IL118262A0 (en) Isoxazolines and pharmaceutical compositions containing them
IL111721A0 (en) Isoxazolines and isoxazoles and pharmaceutical compositions containing them
ES2120713T3 (es) Compuestos de isoxazolinas utiles como antagonistas de receptores del fibrinogeno.
ATE178614T1 (de) Zyklische verbindungen zur verwendung als inhibitoren des glycoprotein iib/iiia
IL162917A0 (en) A lysin from bacteriophage and pharmaceutical compositions containing the same
ATE381533T1 (de) Pharmazeutisch wirksame verbindungen und methoden zu ihrer anwendung
WO2005035495A3 (en) Fibrinogen receptor antagonists and their use
DE60118956D1 (de) Calciumkanalantagonisten vom n-typ zur behandlung von schmerzen
WO2000029406A3 (en) Novel isoxazoline fibrinogen receptor antagonists
TR200103638T2 (tr) IL-8 Reseptör antagonistleri
DE69429856D1 (de) Substituierte caprolactame und deren derivate verwendbar zur behandlung der hiv-krankheit
MX9709081A (es) Nuevos antagonistas del receptor fibrinogeno de isoxazolina e isoxazol.
BR0115364A (pt) Tratamento de disfunção sexual
SE7909106L (sv) Nya aryltrifluoretanoler, sett att framstella dessa samt deras anvendning som terapeutika
BR0107179A (pt) Amidinas cìclicas e acìclicas e composições farmacêuticas contendo as mesmas para uso como agentes de ligação de receptor de progesterona
MX2021011588A (es) Antagonistas del receptor muscarinico de acetilcolina subtipo 4 en el tratamiento de la anemia.
CL2024000226A1 (es) Antagonistas del receptor muscarínico 4 y métodos de uso.
GB189622666A (en) Improvements in the Treatment of Ground Slags Intended for Use as Fertilisers.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 730589

Country of ref document: ES